Table 2 HIV-positive patients with NSCLC
From: Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
| Â | Age (Years) | ECOG performance status | Histology | Stage | Site of metastasis | Treatment | Response | Survival (months) |
1 | 50 | 3 | Squamous | IV | Bone | Chemotherapy | PD | 2 |
2 | 58 | 2 | Adeno | IV | Bone | Palliative | Â | 2 |
3 | 44 | 1 | Squamous | IIIB | Â | Chemotherapy | PR | 5 |
4 | 48 | 4 | Squamous | IV | Brain | Chemotherapy | PR | 5 |
5 | 57 | 4 | Adeno | IIIB | Â | Chemotherapy | PR | 3 |
6 | 45 | 1 | Adeno | IIIB | Â | Chemotherapy | PR | 15+ |
7 | 43 | 3 | Adeno | IV | Bone | Chemotherapy | PD | 2 |
8 | 32 | 2 | Adeno | IIIB | Â | Chemotherapy | SD | 8 |
9 | 43 | 2 | Adeno | IV | Bone | Chemotherapy | SD | 7 |
